KalVista Pharma Secures $75M Loan Facility

TL;DR

KalVista just got a $75M loan from Hercules Capital to fund drug development.

AI Summary

On July 22, 2024, KalVista Pharmaceuticals, Inc. entered into a material definitive agreement, specifically a loan and security agreement with Hercules Capital, Inc. This agreement provides KalVista with a term loan facility of up to $75 million, with an initial tranche of $25 million available immediately.

Why It Matters

This significant financing provides KalVista with crucial capital to advance its pipeline, potentially accelerating the development of its drug candidates.

Risk Assessment

Risk Level: medium — The company is taking on debt, which introduces financial risk, but it's for pipeline advancement which is a common biotech strategy.

Key Numbers

• $75.0M — Loan Facility (Maximum amount available from Hercules Capital.)
• $25.0M — Initial Tranche (Amount immediately available to KalVista.)

Key Players & Entities

• KalVista Pharmaceuticals, Inc. (company) — Registrant
• Hercules Capital, Inc. (company) — Lender
• $75 million (dollar_amount) — Total loan facility amount
• $25 million (dollar_amount) — Initial tranche available
• July 22, 2024 (date) — Date of agreement

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share KALV The Nasdaq
• $11.2 million — the term of the Lease is approximately $11.2 million. The Company will post a security dep
• $652,800 — ost a security deposit of approximately $652,800 in the form of a letter of credit, whic

Filing Documents

• kalv-20240722.htm (8-K) — 38KB
• 0000950170-24-085653.txt ( ) — 149KB
• kalv-20240722.xsd (EX-101.SCH) — 24KB
• kalv-20240722_htm.xml (XML) — 5KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On July 22, 2024, KalVista Pharmaceuticals, Inc. (the " Company ") entered into a lease agreement, effective as of July 16, 2024 (the " Lease "), with OC 990 Corporate Center Associates, LLC (the " Lessor ") for approximately 32,110 square feet located at 200 Crossing Boulevard, Framingham, MA (the " Premises "). The Company expects to use the Premises as its corporate headquarters, as well as for laboratory space. The commencement date for the Lease is on or about April 30, 2025, and the Lease will expire in its entirety on December 31, 2034. The aggregate estimated base rent payments due over the term of the Lease is approximately $11.2 million. The Company will post a security deposit of approximately $652,800 in the form of a letter of credit, which is subject to use by the Lessor under certain circumstances, per the terms of the Lease. The Lease contains customary provisions requiring the Company to pay its pro rata share of operating expenses and certain taxes, assessments and fees related to the Premises and provisions allowing the Lessor to terminate the Lease if the Company fails to remedy a breach of certain of its obligations within specified time periods. The foregoing description of the Lease is qualified in its entirety by reference to the Lease, a copy of which will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended July 31, 2024. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of Registrant. The information set forth above in Item 1.01 of this Current Report on Form 8-K regarding the Lease is incorporated into this Item 2.03 by reference.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. KALVISTA PHARMACEUTICALS, INC. Date: July 23, 2024 By: /s/ Benjamin L. Palleiko Benjamin L. Palleiko Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR